: Ever since its discovery, human immunodeficiency virus type 1 (HIV-1) infection has remained a significant public health concern. The number of HIV-1 seropositive individuals currently stands at 40.1 million, yet definitive treatment for the virus is still unavailable on the market. Vaccination has proven to be a potent tool in combating infectious diseases, as evidenced by its success against other pathogens. However, despite ongoing efforts and research, the unique viral characteristics have prevented the development of an effective anti-HIV-1 vaccine. In this review, we aim to provide an historical overview of the various approaches attempted to create an effective anti-HIV-1 vaccine. Our objective is to explore the reasons why specific methods have failed to induce a protective immune response and to analyze the different modalities of immunogen presentation. This trial is registered with NCT05414786, NCT05471076, NCT04224701, and NCT01937455.

The Question of HIV Vaccine: Why Is a Solution Not Yet Available? / M. Libera, V. Caputo, G. Laterza, L. Moudoud, A. Soggiu, L. Bonizzi, R.A. Diotti. - In: JOURNAL OF IMMUNOLOGY RESEARCH. - ISSN 2314-7156. - 2024:(2024 Apr), pp. 2147912.1-2147912.20. [10.1155/2024/2147912]

The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

G. Laterza;A. Soggiu;L. Bonizzi
Penultimo
;
2024

Abstract

: Ever since its discovery, human immunodeficiency virus type 1 (HIV-1) infection has remained a significant public health concern. The number of HIV-1 seropositive individuals currently stands at 40.1 million, yet definitive treatment for the virus is still unavailable on the market. Vaccination has proven to be a potent tool in combating infectious diseases, as evidenced by its success against other pathogens. However, despite ongoing efforts and research, the unique viral characteristics have prevented the development of an effective anti-HIV-1 vaccine. In this review, we aim to provide an historical overview of the various approaches attempted to create an effective anti-HIV-1 vaccine. Our objective is to explore the reasons why specific methods have failed to induce a protective immune response and to analyze the different modalities of immunogen presentation. This trial is registered with NCT05414786, NCT05471076, NCT04224701, and NCT01937455.
Settore MED/07 - Microbiologia e Microbiologia Clinica
Settore VET/05 - Malattie Infettive degli Animali Domestici
apr-2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
2147912.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.44 MB
Formato Adobe PDF
1.44 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1050622
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact